Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of Titan Pharmaceuticals stock opened at $6.88 on Wednesday. The stock’s 50 day simple moving average is $7.27 and its 200-day simple moving average is $7.07. The stock has a market cap of $6.29 million, a P/E ratio of -0.84 and a beta of 1.32. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $16.60.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.